2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd points
2023
Functional status and therapy for older adults with diffuse large B‐cell lymphoma in nursing homes: A population‐based study
Di M, Keeney T, Belanger E, Huntington S, Olszewski A, Panagiotou O. Functional status and therapy for older adults with diffuse large B‐cell lymphoma in nursing homes: A population‐based study. Journal Of The American Geriatrics Society 2023, 71: 2239-2249. PMID: 36882865, PMCID: PMC10483014, DOI: 10.1111/jgs.18302.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaCommunity-dwelling patientsB-cell lymphomaOverall survivalNH patientsCognitive impairmentOdds ratioEnd Results-Medicare databaseAnthracycline-containing regimensDays of diagnosisPopulation-based studyMultivariable logistic regressionPoor overall survivalConfidence intervalsHigh-risk populationAlternative treatment strategiesNursing home careOlder patientsNH residentsFunctional statusPatient preferencesChemoimmunotherapyTreatment strategiesCell lymphoma
1999
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley M, Schuchter L, Lindley C, Meropol N, Cohen G, Broder G, Gradishar W, Green D, Langdon R, Mitchell R, Negrin R, Szatrowski T, Thigpen J, VonHoff D, Wasserman T, Winer E, Pfister D. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal Of Clinical Oncology 1999, 17: 3333-55. PMID: 10506637, DOI: 10.1200/jco.1999.17.10.3333.Peer-Reviewed Original ResearchConceptsUse of dexrazoxaneMetastatic breast cancerClinical practice guidelinesUrothelial toxicityTumor protectionBreast cancerInsufficient evidencePractice guidelinesClinical Oncology Clinical Practice GuidelineLong-term patient qualityOncology Clinical Practice GuidelineStem cell transplantation settingUse of mesnaAnthracycline-containing regimensCardiac risk factorsUse of chemotherapyGrades of RecommendationRadiotherapy-related toxicityMultidisciplinary expert panelLong-term chemotherapyClinical treatment trialsDuration of treatmentLevel of evidenceReduction of nephrotoxicityAmerican Society
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply